Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial
Authors:
- Jeffrey R. StrawnJSJeffrey R. Strawn
- Ethan A. PoweleitEPEthan A. Poweleit
- Jeffrey A. MillsJMJeffrey A. Mills
- Heidi K. SchroederHSHeidi K. Schroeder
- Zoe A. NeptuneZNZoe A. Neptune
- Ashley M. SpechtASAshley M. Specht
- Jenni E. FarrowJFJenni E. Farrow
- Xue ZhangXZXue Zhang
- Lisa J. MartinLMLisa J. Martin
- Laura B. RamseyLaura B. Ramsey
Open Access
- 12 November 2021
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (11) , 1188
Abstract
Current pharmacologic treatments for pediatric anxiety disorders (e.g., selective serotonin reuptake inhibitors (SSRIs)) frequently use “one size fits all” dosing strategies based on average responses in clinical trials. However, for some SSRIs, including escitalopram, variation in CYP2C19 activity produces substantial variation in medication exposure (i.e., blood medication concentrations). This raises an important question: would refining current SSRI dosing strategies based on CYP2C19 phenotypes increase response and reduce side effect burden? To answer this question, we designed a randomized, double-blind trial of adolescents 12–17 years of age with generalized, separation, and/or social anxiety disorders (N = 132). Patients are randomized (1:1) to standard escitalopram dosing or dosing based on validated CYP2C19 phenotypes for escitalopram metabolism. Using this approach, we will determine whether pharmacogenetically-guided treatment—compared to standard dosing—produces faster and greater reduction in anxiety symptoms (i.e., response) and improves tolerability (e.g., decreased risk of treatment-related activation and weight gain). Secondarily, we will examine pharmacodynamic variants associated with treatment outcomes, thus enhancing clinicians’ ability to predict response and tolerability. Ultimately, developing a strategy to optimize dosing for individual patients could accelerate response while decreasing side effects—an immediate benefit to patients and their families. ClinicalTrials.gov Identifier: NCT04623099.Keywords
Funding Information
- National Institute of Child Health and Human Development (R01HD099775)
This publication has 72 references indexed in Scilit:
- Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 in European- and African-American subjects from the National Institute of Mental Health’s Collaborative Center for Genomic StudiesTranslational Psychiatry, 2013
- Defining Treatment Response and Remission in Child Anxiety: Signal Detection Analysis Using the Pediatric Anxiety Rating ScaleJournal of the American Academy of Child & Adolescent Psychiatry, 2013
- Antidepressant Exposure as a Predictor of Clinical Outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) StudyJournal of Clinical Psychopharmacology, 2011
- Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methodsChild and Adolescent Psychiatry and Mental Health, 2010
- Polymorphisms in GRIK4, HTR2A, and FKBP5 Show Interactive Effects in Predicting Remission to Antidepressant TreatmentNeuropsychopharmacology, 2009
- Activation Adverse Events Induced by the Selective Serotonin Reuptake Inhibitor Fluvoxamine in Children and AdolescentsJournal of Child and Adolescent Psychopharmacology, 2009
- Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood AnxietyNew England Journal of Medicine, 2008
- SLC6A4 variation and citalopram responseAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008
- Serotonin Transporter Promoter Gain-of-Function Genotypes Are Linked to Obsessive-Compulsive DisorderThe American Journal of Human Genetics, 2006
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005